Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

Jian L. Campian; Xiaobu Ye; Guneet Sarai; Joseph Herman; Stuart A. Grossman

doi:10.1080/07357907.2018.1499028

Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

Jian L. Campian, Xiaobu Ye, Guneet Sarai, Joseph Herman, Stuart A. Grossman

Section of Medical Oncology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm³ (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

Original language	English
Pages (from-to)	356-361
Number of pages	6
Journal	Cancer Investigation
Volume	36
Issue number	6
DOIs	https://doi.org/10.1080/07357907.2018.1499028
State	Published - Jul 3 2018

Keywords

Lymphopenia
Radiation
Rectal cancer

Access to Document

10.1080/07357907.2018.1499028

Cite this

@article{f87cc4a16dd64228b051f20cc68d7a68,

title = "Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer",

abstract = "Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL{\textquoteright}s relationship to survival.",

keywords = "Lymphopenia, Radiation, Rectal cancer",

author = "Campian, {Jian L.} and Xiaobu Ye and Guneet Sarai and Joseph Herman and Grossman, {Stuart A.}",

year = "2018",

month = jul,

day = "3",

doi = "10.1080/07357907.2018.1499028",

language = "English",

volume = "36",

pages = "356--361",

journal = "Cancer Investigation",

issn = "0735-7907",

number = "6",

}

TY - JOUR

T1 - Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

AU - Campian, Jian L.

AU - Ye, Xiaobu

AU - Sarai, Guneet

AU - Herman, Joseph

AU - Grossman, Stuart A.

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

AB - Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

KW - Lymphopenia

KW - Radiation

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85052156287&partnerID=8YFLogxK

U2 - 10.1080/07357907.2018.1499028

DO - 10.1080/07357907.2018.1499028

M3 - Article

C2 - 30095290

AN - SCOPUS:85052156287

SN - 0735-7907

VL - 36

SP - 356

EP - 361

JO - Cancer Investigation

JF - Cancer Investigation

IS - 6

ER -

Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this